Related Experiment Video
Updated: Aug 3, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Upregulation of NADH/NADPH oxidase 4 by angiotensin II induces podocyte apoptosis
Tae-Sun Ha1,2, Su-Bin Seong1, Dong-Soo Ha3
1Department of Pediatrics, Chungbuk National University College of Medicine, Cheongju, Republic of Korea.
Background:
Angiotensin II induces glomerular and podocyte injury via systemic and local vasoconstrictive or non-hemodynamic effects including oxidative stress. The release of reactive oxygen species (ROS) from podocytes may participate in the development of glomerular injury and proteinuria. We studied the role of oxidative stress in angiotensin II-induced podocyte apoptosis.
Methods:
Mouse podocytes were incubated in media containing various concentrations of angiotensin II at different incubation times and were transfected with NADH/NADPH oxidase 4 (Nox4) or angiotensin II type 1 receptor for 24 hours. The changes in intracellular and mitochondrial ROS production and podocyte apoptosis were measured according to the presence of angiotensin II.
Results:
Angiotensin II increased the generation of mitochondrial superoxide anions and ROS levels but suppressed superoxide dismutase activity in a dose- and time-dependent manner that was reversed by probucol, an antioxidant. Angiotensin II increased Nox4 protein and expression by a transcriptional mechanism that was also reversed by probucol. In addition, the suppression of Nox4 by small interfering RNA (siRNA) reduced the oxidative stress induced by angiotensin II. Angiotensin II treatment also upregulated AT1R protein. Furthermore, angiotensin II promoted podocyte apoptosis, which was reduced significantly by probucol and Nox4 siRNA and also recovered by angiotensin II type 1 receptor siRNA.
Conclusion:
Our findings suggest that angiotensin II increases the generation of mitochondrial superoxide anions and ROS levels via the upregulation of Nox4 and angiotensin II type 1 receptor. This can be prevented by Nox4 inhibition and/or antagonizing angiotensin II type 1 receptor as well as use of antioxidants.
Insights
Angiotensin II triggers oxidative stress and podocyte apoptosis by increasing reactive oxygen species (ROS) via Nox4 and AT1R. Antioxidants or inhibiting Nox4/AT1R can prevent this injury.
Area of Science:
- Nephrology
- Molecular Biology
- Oxidative Stress Research
Background:
- Angiotensin II contributes to kidney podocyte injury through oxidative stress.
- Reactive oxygen species (ROS) from podocytes are implicated in glomerular damage and proteinuria.
Purpose of the Study:
- To investigate the role of oxidative stress in angiotensin II-induced podocyte apoptosis.
- To elucidate the involvement of Nox4 and angiotensin II type 1 receptor (AT1R) in this process.
Main Methods:
- Mouse podocytes were treated with angiotensin II and transfected with Nox4 or AT1R.
- Intracellular/mitochondrial ROS production and apoptosis were measured.
- Nox4 and AT1R expression/protein levels were analyzed.
Main Results:
- Angiotensin II increased mitochondrial ROS and suppressed superoxide dismutase activity.
- Angiotensin II upregulated Nox4 and AT1R expression via transcriptional mechanisms.
- Inhibiting Nox4 or AT1R, or using the antioxidant probucol, reduced ROS and podocyte apoptosis.
Conclusions:
- Angiotensin II elevates mitochondrial ROS via Nox4 and AT1R upregulation.
- Inhibiting Nox4, antagonizing AT1R, or using antioxidants can prevent angiotensin II-induced podocyte injury.
More Related Videos
12:19Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli
Published on: June 27, 2015
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
Related Concept Videos
Hormonal Regulation
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Acute Kidney Injury II: Pathophysiology
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Hypertension II: Pathophysiology